How to give bleomycin in cystic hygroma
Reading File
Finding Sources
Finding Sources
Searching PubMed
bleomycin sclerotherapy cystic hygroma lymphatic malformation
Reading File
Reading File
Searching PubMed
bleomycin sclerotherapy lymphatic malformation
Reading File
Finding Sources
Reading Article
PMID: 37423005
Finding Sources
Finding Sources
Reading File
Reading File
Searching the Web
bleomycin injection cystic hygroma dose technique protocol mg/kg
Reading File
Reading File
I now have all the information needed. Let me compile the comprehensive answer.
Bleomycin in Cystic Hygroma - Complete Guide
Bleomycin is used as an intralesional sclerosing agent for cystic hygroma (macrocystic lymphatic malformation) when complete surgical excision is not feasible. It works by causing endothelial damage and fibrosis within the cyst walls.
When to Use Bleomycin
- Primary indication: when complete surgical excision is not feasible (Sabiston Textbook of Surgery, p. 2674)
- First-line agent for macrocystic disease - responds better than microcystic lesions
- Microcystic/mixed lesions have lower response rates
- Bleomycin is preferred over absolute alcohol (less painful) and is considered the agent of choice at many centers - Cummings Otolaryngology, p. 2621
Preparation
| Parameter | Detail |
|---|---|
| Drug form | Bleomycin sulfate (aqueous solution) |
| Concentration | Reconstituted in normal saline or water for injection |
| Formulation used | Standard aqueous; also reported as bleomycin fat emulsion (Tanigawa method) |
Dose
There is no single universally accepted dose, but reported protocols are:
| Method | Dose |
|---|---|
| Yura method (classical) | 1 mg/kg per session, injected after aspirating cyst contents; max single dose 15 mg |
| Standard range (most series) | 0.3 - 0.6 mg/kg per session |
| Common practical dose | 0.4 - 0.6 mg/kg depending on lesion size |
| Microcystic/interventional radiology | 1 U/kg per session, max 15 U per session |
| Maximum cumulative dose | 5 mg/kg total body weight |
A 2023 meta-analysis (21 studies, 428 patients) found the combined effective rate was 84% (95% CI 0.81-0.87), and weight-based dosing (86%) outperformed fixed-dose dosing (74%). - Sun et al., Braz J Otorhinolaryngol, 2023 PMID 37423005
Step-by-Step Technique
1. Pre-procedure imaging
- Review MRI (T2 hyperintense - confirms extent) or ultrasound
- Classify as macrocystic (≥2 cm cysts), microcystic, or mixed
- Macrocystic responds best
2. Anesthesia
- Performed under general anesthesia (especially in children)
- IV sedation is an alternative in cooperative patients
- If lesion involves the airway: add dexamethasone 0.5 mg/kg IV intraprocedurally
3. Antibiotic prophylaxis
- If lesion involves oral cavity: cefazolin 25 mg/kg IV single pre-procedure dose
4. Access and contrast injection (for macrocystic - fluoroscopy-guided)
- Access the cyst using an 18-gauge Angiocath or 21- to 25-gauge needle under ultrasound guidance
- Inject contrast medium to confirm intracystic placement and map the full extent of the lesion (road-map fluoroscopy)
- Verify opacification of the entirety of the lesion - Cummings Otolaryngology, p. 2621 (Fig. 136.10)
5. Aspiration of cyst contents
- Aspirate as much cyst fluid as possible before bleomycin injection (classical Yura approach)
- Note: some centers skip aspiration (particularly for microcystic disease with USG-guided injection)
6. Bleomycin injection
- Inject bleomycin aqueous solution at the calculated dose directly into the cyst cavity
- For multiloculated/septated lesions: divide the calculated dose among the individual cysts/septae
- Inject under sonographic and/or fluoroscopic guidance
- For microcystic disease: inject into the lesion substance without aspiration
7. Post-injection
- Observe; the sclerosant remains in the cyst
- Patient may be discharged after observation, or kept overnight if airway involvement
Repeat Injections
| Parameter | Protocol |
|---|---|
| Interval between sessions | 2-6 weeks (range 2 weeks to 2 months) |
| Number of sessions | Up to 16 sessions reported; typically 3-6 |
| Stop criteria | No further response after 2 injections, or complete resolution |
| Lesions < 1 cm | Not treated with bleomycin (too small) |
Response by Lesion Type
| Type | Response |
|---|---|
| Macrocystic | Best (complete regression ~63%, significant involution up to 88%) |
| Mixed | Variable - still reasonable first-line option |
| Microcystic | Lower response (poor response in 12-18% of patients) |
Complications and Precautions
- Local: Swelling and cellulitis-like reaction (expected), skin necrosis (rare), infection
- Pulmonary toxicity: Bleomycin is a recognized cause of pulmonary fibrosis - keep cumulative dose below 5 mg/kg to minimize risk
- Systemic: Fever, flu-like symptoms
- Avoid in patients with pre-existing lung disease
Comparison with Other Sclerosants
| Agent | Notes |
|---|---|
| Bleomycin | Less painful than alcohol, effective, agent of choice at most centers |
| OK-432 (Picibanil) | Best evidence for macrocystic disease; not FDA-approved in USA; requires aspiration first |
| Doxycycline | Effective, widely available, less systemic toxicity concern |
| Absolute ethanol | Very effective but painful; more risk of nerve and skin damage |
Sources:
- Sabiston Textbook of Surgery (p. 2674) - sclerosants for cystic hygroma
- Cummings Otolaryngology Head and Neck Surgery (p. 2621) - bleomycin as agent of choice, fluoroscopy technique
- Sun et al., 2023 meta-analysis - 84% effective rate, weight-based dosing superior
This is a shared conversation. Sign in to Orris to start your own chat.